Some thoughts on the article; first, Ted is not just anybody, he knows the topic and is a smart well educated (MBA, CFA) insider.
"It may be a strong indication that Altria has fomented a corporate culture that is inconsistent with modern standards of acceptable behavior and business success." - interesting comment. Maybe this is what it actually boils down to? Chris Bunka don`t deserve any disrespect full BS, big cooperation or not. Mutual respect goes a long way; maybe we will see a new better deal further ahead.
Chris; "In what amounted to a $1 million research project funded by Altria, we think the scientific work on our technology was an absolute success. LXRP learned a lot about the technology and have already deployed that knowledge into the current DehydraTECH™ formulation to improve it for nicotine, other applications and our intellectual property portfolio. So it was a very worthwhile experience that produced extremely valuable, tangible results."
This is the professional response to what went down; the ability to see the benefits and long term value - especially with uplisting within 2-3 months. Getting access to big pocket players on a major stockexchange is a milestone
"We are in the manufacturing stage and after that there is a lot of testing that has to take place to make sure DehydraTECH™ meets various standards. We will make delivery sometime in November and that’s when BATS’ analysis will start." Manufacturing, check. Delivery next month, check. Taken this far already, the BAT collaboration has moved quick! Look out for test results and a signed deal, it`s clear that BAT is moving this to market as fast they can.
I will finish here, though encourage all shareholders and other interested parties, to read the interview with Chris (again). He is refreshingly open and clear; this gives a strong indication that Lexaria Bioscience has a bright future.
